Post by Egle Therapeutics

We’re looking forward to participating in #Citi's 2nd Annual Virtual Biotech Investor Conference next week on Wednesday, April 22!​ ​ Our team, including CEO John Celebi, is excited to detail recent updates on our Treg-targeting pipeline programs with the investment community, including progress with EGL-003 as a potential treatment for atopic dermatitis and funding from the European Union to support EGL-001’s clinical development in neoadjuvant head and neck cancer.​ ​ We’d welcome the opportunity to connect if you’ll be attending. To learn more about Egle, visit www.egle-tx.com.